The IV formulation of edaravone was approved under the brand name Radicava ® in May 2017 for the treatment of ALS. The retrospective, observational, comparative effectiveness cohort study ...

The study suggests that, in patients with amyotrophic lateral sclerosis (ALS), treatment with intravenous (IV) RADICAVA ® (edaravone) was associated with fewer reported disease progression ...

Please provide your email address to receive an email when new articles are posted on . The treatment group logged longer times to four disease-progression milestones compared with controls.

Mitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements from the EMA. The drug has been approved in the ...